- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Agios Pharm (AGIO)Agios Pharm stock price live, this page displays NASDAQ AGIO stock exchange data. View the AGIO premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Agios Pharm real time stock price chart below.
What Is the Agios Pharm Stock Price Today?
The Agios Pharm stock price today is 61.64.
What Is the Stock Symbol for Agios Pharm?
The stock symbol for Agios Pharm is "AGIO."
What Stock Exchange Does Agios Pharm Trade On?
Agios Pharm is listed and trades on the NASDAQ stock exchange.
Is Agios Pharm a Good Stock to Buy?
Determining whether Agios Pharm—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AGIO quote. (ISIN: US00847X1046)
What Is the Agios Pharm Stock Price Today?
The Agios Pharm stock price today is 61.64.
What Is the Stock Symbol for Agios Pharm?
The stock symbol for Agios Pharm is "AGIO."
What Stock Exchange Does Agios Pharm Trade On?
Agios Pharm is listed and trades on the NASDAQ stock exchange.
Is Agios Pharm a Good Stock to Buy?
Determining whether Agios Pharm—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AGIO quote. (ISIN: US00847X1046)
61.64
+2.67(+4.53%)
Closed
After Hours
61.17-0.47(-0.76%)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
59.09
62.45
52 wk Range
20.96
62.58
AGIO Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
59.0962.45
52 wk Range
20.9662.58
Key Statistics
Edit
Book Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
UnlockN/A
(N/A)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockBook Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
UnlockN/A
(N/A)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockAGIO Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Buy
Price Target
53.88
Downside
-12.59%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
- Agios stock soars to 52-week high, reaching $53.28
- Investing.com
- Agios stock soars to 52-week high, reaching $53.28
- Investing.com
Agios Pharm Company Profile
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Agios Pharm SWOT Analysis
Navigating Turbulence | Agios faces challenges in the sickle cell disease market while pursuing opportunities in thalassemia and myelodysplastic syndromes, shaping its strategic direction. |
Financial Fortitude | With a robust $1.7 billion cash position, Agios stands ready to fund pipeline development and explore strategic opportunities in the biopharma landscape. |
Pipeline Potential | Explore Agios' diverse portfolio, including Pyrukynd's label expansion and emerging therapies, poised to drive future growth in genetic diseases and oncology. |
Market Dynamics | Analyst targets range from $55 to $56, reflecting cautious optimism amidst regulatory uncertainties and potential market share gains in sickle cell disease. |
AGIO Full Pro Research
Institutional-Grade Stock Analysis
Understand how AGIO earns money
Financial health at a glance
Bearish and bullish outlooks
Latest expert insights
Actionable Pro Tips, and many more...
Gain access to 1400+ in-depth research reports on the most popular US stocks
Agios Pharm Earnings Call Summary for Q4/2024
- Revenue surge: $1.1B milestone payments from FDA approval of vorasidenib; Q3 PYRUKYND revenue $9M, up 22% YoY
- Product launches: Mitapivat for thalassemia (2025) and sickle cell disease (2026); Phase 3 RISE UP study enrollment complete
- Financial position: $1.7B in cash and equivalents at quarter-end; focused on rare blood disease treatments
- Regulatory progress: FDA orphan drug designation for tebapivat; plans to submit sNDA for mitapivat in thalassemia by year-end
- Market outlook: Mitapivat seen as potential multibillion-dollar treatment; addressing concerns in African trial sites
Last Updated: 02/11/2024, 12:28 am
Read Full TranscriptCompare AGIO to Peers and Sector
Metrics to compare | AGIO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAGIOPeersSector | |
|---|---|---|---|---|
P/E Ratio | 5.2x | −1.0x | −0.6x | |
PEG Ratio | 0.01 | 0.06 | 0.00 | |
Price/Book | 2.2x | 1.0x | 2.6x | |
Price / LTM Sales | 106.9x | 24.3x | 3.2x | |
Upside (Analyst Target) | −9.9% | 327.3% | 44.6% | |
Fair Value Upside | Unlock | 8.5% | 7.3% | Unlock |
Analysts' Recommendations
7 Buy
3 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 53.88
(-12.60% Downside)
People Also Watch
FAQ
What Is the Agios Pharm (AGIO) Stock Price Today?
The Agios Pharm stock price today is 61.64
What Stock Exchange Does Agios Pharm Trade On?
Agios Pharm is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for Agios Pharm?
The stock symbol for Agios Pharm is "AGIO."
What Is the Agios Pharm Market Cap?
As of today, Agios Pharm market cap is 3.52B.
What is Agios Pharm Earnings Per Share?
The Agios Pharm EPS is 11.93.
What Is the Next Agios Pharm Earnings Date?
Agios Pharm will release its next earnings report on 12 Feb 2025.
From a Technical Analysis Perspective, Is AGIO a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.